Videos

Luciano J. Costa, MD, PhD, discussed the future treatments being evaluated for the treatment of multiple myeloma.

Dr Daniel H. Ahn explains the logistical concerns of ctDNA testing in colorectal cancer.

Aparna Parikh, MD, MS, defines circulating tumor DNA (ctDNA) and the use of ctDNA assays in colorectal cancer.

Shared insight from Terri Blalock and her caregiver, Kaitlin Blalock, regarding the diagnosis of renal cell carcinoma Terri received following a number of symptoms.

Expert oncologist Hans Hammers, MD, PhD, spearheads an overview on renal cell carcinoma, covering its current incidence and known risk factors.

Shared insight on the development of CAR T-cell therapies and their use in the later-line setting for patients with multiply relapsed multiple myeloma.

Expert perspectives on the combination of novel bispecific therapies and where they may fit into the treatment paradigm of relapsed/refractory multiple myeloma.

Luciano J. Costa, MD, PhD, discussed additional studies evaluating various treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma, aiming to determine the best standard in this population.

The panel continues their discussion on infection risk with a look at the immunosuppressive effects of BCMA-targeting bispecifics.

The panel discusses the importance of discussing COVID with patients with multiple myeloma and stressing the need to get vaccinated.

Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.

Luciano J. Costa, MD, PhD, discussed the results from the phase 2 GRIFFIN study, designed to evaluate the combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in transplant-eligible patients with multiple myeloma.

Expert oncologists discuss treatment options in the setting of recurrent triple-negative breast cancer.

Hope S. Rugo, MD, FASCO, and Paolo Tarantino, MD compare treatment approaches for HER2-low and triple-negative breast cancer.

Shared perspective on the potential role of ADCs, CAR T-cell therapy, and other agents in combination treatment with bispecifics for patients with multiple myeloma.

Focusing their discussion on clinical data in R/R multiple myeloma studies, panelists highlight current and emerging bispecific antibodies for treating patients that have progressed after multiple lines of therapy.

Luciano J. Costa, MD, PhD discussed updating findings from the phase 3 MAIA trial of the triplet combination of daratumumab, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma.

Closing out their discussion on the management of multiple myeloma, expert panelists highlight unmet needs and look toward future directions in care.

An expert from Chase Comprehensive Cancer Center discusses how findings from a genomic analysis of the phase 2 BLASST-1 trial may identify biomarkers of response and resistance to nivolumab/chemotherapy in muscle-invasive bladder cancer.

Expert perspectives on the typical patient workup that occurs in oncology practice to identify cardiovascular risk.

Cardiologist Anees A. Daud, MD, elucidates examinations and tests that help to identify cardiovascular risk in practice.

Medical oncologist Joelle Hamilton, MD, reflects on the prevalence of cardiovascular risk while managing prostate cancer in patients.

Direct insight from a cardiologist on the advent of cardiovascular risk when treating a patient for prostate cancer.

Before closing out their discussion on multiple myeloma management, panelists reflect on real-world clinical practice perspectives on treatment with bispecifics.

Paolo Tarantino, MD, an expert on breast cancer, gives an overview of neoadjuvant treatment options for triple-negative breast cancer.

Breast cancer experts Hope S. Rugo, MD, FASCO, and Paolo Tarantino, MD, present the case of a 52-year-old woman with triple-negative breast cancer and provide their initial thoughts.

The panel discusses other emerging biomarkers for monitoring patient response to therapy for colorectal cancer.

The panel shares some final thoughts on unmet needs and the future of CLL treatment.

Dr Aparna Parikh explains minimal residual disease (MRD) in colorectal cancer and the logistical challenges of MRD testing.

Dr Alexey Danilov explains data on emerging therapies, including anti-ROR1 therapies, BTK degrading agents, and bispecifics, for treatment of CLL.